Billionaire Investor Targets BMS

Feb 22, 2017

Activist investor Carl Icahn disclosed his stake in Bristol-Myers Squibb, fueling rumors that the company may be split up or sold.

Last week, StreetInsider reported that based on industry sources, Bristol-Myers Squibb was a prime target for takeover following the Opdivo setback, with at least three potential suitors -- Roche, Pfizer and Novartis. In January, BMS announced that it won't seek accelerated approval of its immunotherapy drug Opdivo for lung cancer, confirming that Merck would have a huge head start with its rival treatment Keytruda.

Icahn's involvement is known to cause shakeups and in this case, a potential sale or split could reshape the immuno-oncology landscape.

Read the Forbes article

 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments